Agenzia Italiana del Farmaco
Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion - Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion
Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion
Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion:
risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion.
Summary
- There is a risk of medication errors due to the presence on the market of different cabazitaxel presentations:
- Cabazitaxel Accord (20 mg/mL) concentrate for solution for infusion requires a single-step dilution process;
- Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion requires a two-step dilution process.
- Before the final dilution step either in glucose solution or sodium chloride solution for infusion, the concentration of cabazitaxel is:
- 20 mg/ml for Cabazitaxel Accord
- 10 mg/ml for Jevtana
- A mix-up between the products may lead to medication errors resulting in either overdosing with potentially fatal outcome, or underdosing with reduction of therapeutic effect (see background section below).
- Always check carefully which product is being used and the dilution instructions to ensure that the patient receives the correct dose of cabazitaxel.
Published on: 16 June 2021
Si conclude la campagna #MedSafetyWeek di quest’anno! 🎉
Grazie per aver seguito i nostri canali in ...
Vai al post →
Gli operatori sanitari dedicano la loro vita alla sicurezza dei pazienti.
Ecco 4 modi per continuare...
Vai al post →
Come diventare un #MedSafetyHero?
Tutti i pazienti, o tutti coloro che se ne prendono cura, hanno il...
Vai al post →
In #AIFA la Prof.ssa Violeta Stoyanova-Beninska, già Chair del Committee for Orphan Medicinal Produc...
Vai al post →
Il monitoraggio della sicurezza dei medicinali non finisce quando questi raggiungono gli scaffali de...
Vai al post →
La sicurezza dei #farmaci inizia da noi 💊
Come medico, hai un ruolo chiave da svolgere:
✔ Parla dei...
Vai al post →
